Aldo Lourenço Abbade Dettino

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

MRP1 expression in CTCs confers resistance to irinotecan‐based chemotherapy in metastatic colorectal cancer

Emne Ali Abdallah, Marcello Ferretti Fanelli, Virgílio Souza e Silva et al. · International Journal of Cancer · 2016 · 57 citations

Medicine, Oncology, Pharmacology +16

Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5‐fluorouracil resistance in metastatic colorectal cancer patients

Emne Ali Abdallah, Marcello Ferretti Fanelli, Marcilei Eliza Cavicchioli Buim et al. · International Journal of Cancer · 2015 · 55 citations · Full text

Medicine, Oncology, Pharmacology +16

Cytokeratin-based CTC counting unrelated to clinical follow up.

Ludmilla Thomé Domingos Chinen, Fernanda Machado de Carvalho, Bruna Maria Malagoli Rocha et al. · PubMed · 2013 · 48 citations

Medicine, Cell Biology, Oncology +14